Type 1 diabetes control and pregnancy outcomes in women treated with continuous subcutaneous insulin infusion (CSII) or with insulin glargine and multiple daily injections of rapid-acting insulin analogues (glargine–MDI)

Bruttomesso, Daniela; Bonomo, Matteo; Costa, Silvana Daher; Pos, Michela Dal; Cianni, Graziano Di; Pellicano, Francesca; Vitacolonna, Ester; Ar, Dodesini; Tonutti, Laura; Lapolla, Annunziata; Benedetto, A. Di; Torlone, Elisabetta

doi:10.1016/j.diabet.2011.02.002

Cited by 55 publications

(79 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Adults With T1dmmentioning

confidence: 99%

“…[51][52][53][54][55][56] The strength of evidence of the data that compared CSII with MDI among pregnant women with pre-existing T1DM was insufficient for all other maternal and neonatal outcomes due to lack of RCTs and, therefore, a high risk of bias. There was no statistical difference in maternal weight gain, 52,54,56 gestational age at delivery, 51,[53][54][55] birth weight, [53][54][55] and minor congenital anomalies 51,54 between the CSII and MDI intervention groups. Also, meta-analyses of retrospective studies showed nonsignificant relative risks for rates of C-section (RR = 1.01; 95% CI, 0.86-1.20), [53][54][55][56] severe hypoglycemia (RR = 0.78; 95% CI, 0.23-2.65), [54][55][56] admission to the neonatal intensive care unit (RR = 0.84; 95% CI, 0.43-1.68), 54,55 pre-term delivery (RR = 0.98; 95% CI, 0.67-1.43), [53][54][55][56] and frequency of neonatal hypoglycemia (RR = 1.01; 95% CI, 0.86-1.20).…”

Section: Adults With T1dmmentioning

confidence: 99%

“…Also, meta-analyses of retrospective studies showed nonsignificant relative risks for rates of C-section (RR = 1.01; 95% CI, 0.86-1.20), [53][54][55][56] severe hypoglycemia (RR = 0.78; 95% CI, 0.23-2.65), [54][55][56] admission to the neonatal intensive care unit (RR = 0.84; 95% CI, 0.43-1.68), 54,55 pre-term delivery (RR = 0.98; 95% CI, 0.67-1.43), [53][54][55][56] and frequency of neonatal hypoglycemia (RR = 1.01; 95% CI, 0.86-1.20). [53][54][55][56] Additionally, metaanalyses for major congenital anomalies showed a pooled RR of 2.12 that favored MDI but was not statistically significant. 55,56 Due to the lack of RCTs, which leads to a high risk of bias of all the above outcomes, the EPC investigators suggested that results were inconclusive.…”

Section: Adults With T1dmmentioning

confidence: 99%

“…and fetal outcomes. [51][52][53][54][55][56] The mean age of study participants was 26 to 31 years, with most participants in the CSII group enrolled into the studies prior to becoming pregnant. Most participants had diabetes duration of 7.7 to 13.9 years, with participants in the CSII groups having the longest duration of diabetes.…”

Section: Adults With T1dmmentioning

confidence: 99%

See 3 more Smart Citations

Methods for Insulin Delivery and Glucose Monitoring in Diabetes: Summary of a Comparative Effectiveness Review

Golden¹,

Sapir²

2012

JMCP

View full text Add to dashboard Cite

, before training in internal medicine and endocrinology and metabolism at the Johns Hopkins Hospital. During her fellowship in endocrinology, she received a master of health science degree in clinical epidemiology from the Johns Hopkins University Bloomberg School of Public Health. Her primary research interest centers around identifying endocrine risk factors associated with the development of diabetes and cardiovascular disease through the incorporation of measures of hormonal function into the design of clinical trials of cardiovascular risk modification, observational studies of incident cardiovascular disease and diabetes, and studies evaluating diabetic complications. Her current research focuses on studying the neuroendocrine response to chronic psychological stress as a risk factor for diabetes and cardiovascular disease. Dr Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. S15 References Target AudiencesThis CME activity is designed to meet the educational needs of physicians, pharmacists, nurses, and case managers involved in the management and care of patients with diabetes. Learning ObjectivesBased on the findings from the Agency for Healthcare Research and Quality' s (AHRQ) comparative effectiveness review of insulin delivery and glucose-monitoring modalities for diabetes, participants should be able to: 1. Compare the benefits of insulin delivery systems in improving clinical outcomes, glycemic control, hypoglycemia, and quality of life in diabetic patients receiving intensive insulin therapy 2. Evaluate the differential effect of glucose-monitoring approaches on the process measures and intermediate and clinical outcomes in diabetic patients receiving intensive insulin therapy 3. Apply the AHRQ findings to guide effective, patient-centered clinical decisions Funding There is no fee for this CME/CE activity. This learning activity was prepared and funded under contract HHSA290201000006G from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Hea...

show abstract

Section: Adults With T1dmmentioning

confidence: 99%

Section: Adults With T1dmmentioning

confidence: 99%

Section: Adults With T1dmmentioning

confidence: 99%

Section: Adults With T1dmmentioning

confidence: 99%

See 2 more Smart Citations

Methods for Insulin Delivery and Glucose Monitoring in Diabetes: Summary of a Comparative Effectiveness Review

Golden¹,

Sapir²

2012

JMCP

View full text Add to dashboard Cite

show abstract

“…All study centers used the same devices and the same methods of education and training for participants. However, a limitation was that, although studies comparing the use of CSII and MDI have yielded inconsistent results [23,29,[42][43][44][45][46], it was not possible to compare the results of pump use with a control group not using pump therapy and/or pump therapy supported by CGM. Nevertheless, this study offered a unique opportunity to follow a large patient population using standardized insulin-delivery devices to assess the prevalence of pregnancy complications and outcomes.…”

Section: Discussionmentioning

confidence: 99%